License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended September 30,				Nine months ended September 30,
Partner	Drug or Drug Candidate	2014		2013		2014		2013
AstraZeneca AB	MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119)	$	105,000	$	25,000	$	105,001	$	25,016
Baxter Healthcare	BAX 855 (Hemophilia)		9,096		201		10,103		1,499
Roche	PEGASYS® and MIRCERA®		3,200		2,625		9,614		7,875
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		793		779		3,939		14,604
Amgen, Inc.	Neulasta®		1,250		1,250		3,750		3,750
Other			1,217		11,505		14,015		14,451
License, collaboration, and other revenue		$	120,556	$	41,360	$	146,422	$	67,195